Three lines of evidence are presented that low density lipoproteins gently extracted from human and rabbit atherosclerotic lesions (lesion LDL) greatly resembles LDL that has been oxidatively modified in vitro. First, lesion LDL showed many of the physical and chemical properties of oxidized LDL, properties that differ from those of plasma LDL: higher electrophoretic mobility, a higher density, higher free cholesterol content, and a higher proportion of sphingomyelin and lysophosphatidylcholine in the phospholipid fraction. A number of lower molecular weight fragments of apo B were found in lesion LDL, similar to in vitro oxidized LDL. Second, both the intact apo B and some of the apo B fragments of lesion LDL reacted in Western blots with antisera that recognize malondialdehyde-conjugated lysine and 4-hydroxynonenal lysine adducts, both of which are found in oxidized LDL; plasma LDL and LDL from normal human intima showed no such reactivity. Third, lesion LDL shared biological properties with oxidized LDL: compared with plasma LDL, lesion LDL produced much greater stimulation of cholesterol esterification and was degraded more rapidly by macrophages. Degradation of radiolabeled lesion LDL was competitively inhibited by unlabeled lesion LDL, by LDL oxidized with copper, by polyinosinic acid and by malondialdehyde-LDL, but not by native LDL, indicating uptake by the scavenger receptor(s). Finally, lesion LDL (but not normal intimal LDL or plasma LDL) was […] Abstract Three lines of evidence are presented that low density lipoproteins gently extracted from human and rabbit atherosclerotic lesions (lesion LDL) greatly resembles LDL that has been oxidatively modified in vitro. First, lesion LDL showed many of the physical and chemical properties of oxidized LDL, proerties that differ from those of plasma LDL: higher electrophoretic mobility, a higher density, higher free cholesterol content, and a higher proportion of sphingomyelin and lysophosphatidylcholine in the phospholipid fraction. A number of lower molecular weight fragments of apo B were found in lesion LDL, similar to in vitro oxidized LDL. Second, both the intact apo B and some of the apo B fragments of lesion LDL reacted in Western blots with antisera that recognize malondialdehyde-conjugated lysine and 4-hydroxynonenal lysine adducts, both of which are found in oxidized LDL; plasma LDL and LDL from normal human intima showed no such reactivity. Third, lesion LDL shared biological properties with oxidized LDL: compared with plasma LDL, lesion LDL produced much greater stimulation of cholesterol esterification and was de-graded more rapidly by macrophages. Degradation of radiolabeled lesion LDL was competitively inhibited by unlabeled lesion LDL, by LDL oxidized with copper, by polyinosinic acid and by malondialdehyde-LDL, but not by native LDL, indicating uptake by the scavenger receptor(s). Finally, lesion LDL (but not normal intimal LDL or plasma LDL) was chemotactic for monocytes, as is oxidized LDL. These studies provide strong evidence that atherosclerotic lesions, both in man and in rabbit, contain oxidatively modified LDL.
Introduction
Plasma lipoproteins, particularly LDL, are the source of the lipid that accumulates in the atherosclerotic lesion (1, 2) . Monocyte-derived macrophages, which are the precursors of most of the foam cells found in early atherosclerotic lesions (3) (4) (5) (6) , do not take up native LDL rapidly enough in vitro to become foam cells (7) . However, several forms of chemically modified LDL are taken up more rapidly by way of a distinct receptor, the acetyl LDL receptor (7) (8) (9) . Oxidatively modified LDL is also recognized by the acetyl LDL receptor (10) (11) (12) (13) (14) and recent evidence strongly suggests that oxidative modification may play a significant role in atherogenesis in vivo (2, (15) (16) (17) (18) . This proposition is importantly supported by the recent demonstration that antioxidant therapy inhibits atherosclerosis in the Watanabe heritable hyperlipidemic (WHHL)' rabbit ( 15, 16) . Direct demonstration of oxidized LDL in atherosclerotic lesions would considerably strengthen the case for its pathogenetic role. Several groups have reported isolation from the aorta of lipoproteins with altered properties (19) (20) (21) (22) (23) (24) (25) (26) but whether these represent oxidatively modified LDL or other modified forms of LDL remains uncertain.
It is unlikely that oxidative modification of LDL generates a single, reproducible form of modified LDL. More likely the oxidized LDL is a heterogeneous mixture of particles containing molecules that have been modified to different degrees and may even differ qualitatively. During the oxidative degradation of polyunsaturated fatty acids, a variety of reactive aldehyde products are formed and these are capable of attaching covalently to protein, particularly to the epsilon amino groups of lysine residues (2, (27) (28) (29) (30) . Malondialdehyde (MDA) and 4-hydroxynonenal are two examples of such products but there are many others (28) . Haberland et al. (17) , using immunohistochemical techniques, reported evidence for the presence of MDA-LDL in the atherosclerotic lesions of WHHL rabbits. Palinski et al. (18) confirmed this finding and also presented immunohistochemical and immunological evidence for the presence of 4-HNE-conjugated LDL in rabbit aortic lesions. In the latter studies, it was also shown that LDL extracted from such lesions was recognized by antibodies against MDA-LDL.
The LDL molecule is notoriously unstable, readily undergoing oxidation, denaturation and aggregation (31) (32) (33) . For example, Khoo et al. (33) have shown that vortexing a solution of LDL for as little as 30 s leads to extensive self-aggregation. Consequently, there is a real possibility that homogenization of the aorta may introduce artifacts. The methods introduced by Smith (1) and by Yla-Herttuala et al. (24) are designed to avoid conditions that might lead to denaturation or aggregation. In the present studies, we have used the methods of Yla-Herttuala et al. (24) to determine (a) whether LDL gently extracted from the aorta has been altered in any way that might enhance its uptake by macrophages; and, specifically, (b) whether the lesions contain oxidatively modified LDL.
Methods
Materials. Carrier-free Na '25I-iodide was purchased from Amersham Corp. (Arlington, IL). ['4C]Oleate was from Research Products International Corp. (Mount Prospect, IL). Ham's F-10 medium, DME, Iscove's medium and cell culture supplies, including PBS, were from Gibco Laboratories (Grand Island, NY) . PBS used for other than cell culture experiments contained 140 mM NaCl, 3 mM KCI, 8 mM Na2HPO4, 2 mM KH2PO4, and 0.27 mM EDTA (pH 7.4). Butylated hydroxytoluene (BHT) was from J. T. Baker Chemical Co. (Phillipsburg, NJ). Aprotinin, elastatinal, leupeptin, PMSF, polyinosinic acid (poly I), tetramethoxypropane, Coomassie brilliant blue and high molecular weight markers were from Sigma Chemical Co. (St. Louis, MO). D-Phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK) and benzamidine were from Calbiochem-Behring Corp. (La Jolla, CA). Silver staining reagents were from National Diagnostics (Somerville, NJ). Probucol was a gift from the Merrell Dow Research Institute (Cincinnati, OH) and was used as a concentrated ethanol solution.
Agarose electrophoresis gels were from Coming Medical Co. (Palo Alto, CA), and polyacrylamide gradient gels (4-12%, Tefo-Gels) from Novex (Encinitas, CA). Tween 20, nitrocellulose membranes, and Enzymobeads were from Bio-Rad Laboratories (Richmond, CA). Affinity-purified goat anti-human IgG, anti-mouse IgG, anti-rabbit IgG, and anti-guinea pig IgG were from Cooper Biomedical (Malvern, PA). Iodogen was from Pierce Chemical Co. (Rockford, IL). X-Omat autoradiography film was purchased from Eastman Kodak Co. (Rochester, NY).
Collection of arterial specimens. Fresh human abdominal aortas and proximal iliac arteries were obtained from organ donors (n = 6, mean age 40±12 yr) for renal transplants immediately after the surgery, washed with sterile saline, and placed in ice-cold lipoprotein extraction buffer containing antioxidants, protease inhibitors, and antibiotics (see below). Intima and inner media of grossly normal areas and areas containing fibro-fatty atherosclerotic lesions were isolated within 1 h after the removal of the arteries and buffer-soluble lipoproteins were extracted at +4°C (24) . A blood sample from the donor was drawn during surgery into the following preservatives (final concentrations): 2.7 mM EDTA, 2 mM benzamidine, 10 MM probucol, 1 gM PPACK, 0.01% aprotinin, 0.008% chloramphenicol, and 0.008% gentamycin. 1 mM PMSF, 1 mM leupeptin, and 40 MM elastatinal were added to the plasma after the separation of blood cells. Plasma total cholesterol and triglyceride values of the patients were 181±61 and 119±20 mg/dl (mean±SD), respectively.
2-3-yr-old WHHL rabbits were fasted overnight before study. Animals were anesthetized with intramuscular ketamine (35 mg/kg) and xylazine (5 mg/kg) and were exsanguinated by cannulating the right atrium through the jugular vein. Blood samples were taken for the isolation of plasma LDL in the presence of the preservatives listed above. To remove trapped blood from the aorta, the systemic circulation was perfused through the apex of the left ventricle with 2 liters of PBS containing 0.27 mM EDTA and 10.0 MM probucol. The whole aorta from arch to bifurcation was removed and cleaned of loose adventitial tissue. Samples were taken for immunocytochemistry ( 18) and intima-media was immediately dissected at +4°C. Areas containing grossly visible fibro-fatty atherosclerotic lesions were extracted for buffer-soluble lipoproteins. A total of 23 animals were studied. Plasma total cholesterol and triglyceride values were 489±84 and 260±91 mg/dl (mean±SD), respectively.
All procedures were approved by the Committee on Investigations Involving Human Subjects and the Committee on Investigations Involving Animal Subjects of the University of California, San Diego.
Extraction of intimal lipoproteins. Dissected samples were cut into small pieces with a Mcllwain tissue chopper (The Micle Laboratory Engineering Co., UK). Minced tissue or whole plasma was extracted overnight at +4°C under nitrogen using an orbital shaker (10 rpm) in 0.14 M NaCI/0.0l M phosphate buffer, pH 7.2 (24) , which contained the following preservatives (final concentrations): 2.7 mM EDTA, 2 mM benzamidine, 1 mM PMSF, 1 mM leupeptin, 40 MM elastatinal, 10 uM probucol, 1 AM PPACK, 0.01% aprotinin, 0.008% chloramphenicol, and 0.008% gentamycin. Plasma samples from the donors and WHHL rabbits were similarly handled, i.e., incubated in the presence ofthe same preservatives, antioxidants, and antibiotics. A total of 5 ml extraction buffer (24) was used per gram wet tissue or per 5 ml of plasma. The extract was collected by low-speed centrifugation at +4°C and the supernatants were combined. The extract was transferred into 12-ml tubes and overlayered with 0.5 ml of water. The tubes were centrifuged at 100,000 g for 30 min at +5°C. A pellet at the bottom and a creamy layer at the top were discarded. The extract was then concentrated by low-speed centrifugation using Centricon filters (Amicon Corp., Danvers, MA) and subjected to density gradient ultracentrifugation (24) .
Density gradient ultracentrifugation. The density ofthe extract was adjusted to 1.18 g/ml by addition ofsolid NaBr. A 6.50-ml sample was placed in a tube and overlayered with 5.40 ml of the lipoprotein extraction buffer (d = 1.004). The tubes were centrifuged at 150,000 g for 40 h at +5°C in a model L2 ultracentrifuge using a SW41 rotor (Beckman Instruments, Fullerton, CA). A tube containing plasma from the tissue donor or WHHL rabbits and a background salt tube were included in each run. The density profile of the gradient was measured with a densitometer (Mettler-Paar model DMA 45; Anton Paar K.G., Graz, Austria). Lipoproteins were located by their light scattering under indirect illumination and collected by pipetting. LDL fractions were recentrifuged twice at 150,000 g for 24 h at 50C at the density of 1.090 g/ml in the presence of 0.27 mM EDTA, 2 mM benzamidine, 1 mM PMSF, 10 MM probucol, 1 MM PPACK, and antibiotics. In addition to the patient and WHHL rabbit lipoproteins, normal human LDL, and lipoprotein-deficient serum (LPDS) were isolated from healthy volunteers by preparative ultracentrifugation (34) in the presence of the same antioxidants, protease inhibitors, and antibiotics. Characterization ofthe isolated lipoproteins. Protein content ofthe lipoproteins was determined according to Lowry et al. (35) using BSA as a standard. In a separate experiment we tested the ability of the protein assay to measure oxidized LDL protein. Compared with an equal amount of control LDL, LDL oxidized with copper for 20 h gives -10% lower values in the Lowry assay (data not shown). The difference was considered small enough to justify the use of the Lowry assay in the present studies and results were not corrected. Total cholesterol and free and esterified cholesterol were analyzed using a nonenzymatic method (36) . Triglycerides were determined using enzymatic methods (Boehringer-Mannheim Biochemicals, Indianapolis, IN) . Total phospholipids and phospholipid subfractions were analyzed as described (12) . Agarose electrophoresis (12), apo B distribution across the density gradient (37) , and the assay for thiobarbituric acidreactive substances (TBARS) in the lipoproteins (12) were performed as described.
SDS-PAGE and immunoblotting. SDS-PAGE was done using 4-12% gels in 0.025 M Tris 0.19 M glycine buffer, pH 8.3, containing 0.1% SDS (100 V, 30 mA for 75 min; Novex Mini Cell electrophoresis unit, Encinitas, CA). Before the electrophoresis, the samples were heated for 3 min in a boiling water bath. The sample buffer contained 0.063 M Tris-HCI, 2% SDS, 10% glycerol, 10 ,M BHT, and 0.001% bromphenol blue (pH 6.8). Because preliminary experiments showed that the ability of some antibodies (MB-19 [38] , MAL-2, 4-HNE) to react with apolipoproteins was significantly reduced by prior reduction of the samples with 2-mercaptoethanol, the reducing agent was not included in the sample buffer. No difference was found in the electrophoretic mobility of apo B and its fragments in reduced and nonreduced samples. Coomassie brilliant blue and silver stainings were used to visualize protein bands.
Transfer to nitrocellulose membranes for immunoblotting was done in the same electrophoresis unit at +4°C for 80 min (25 V, 160 mA). Transfer buffer contained 0.025 M Tris/0. 19 M glycine, 10 AM BHT, and 15% methanol (vol/vol). After the transfer, nonspecific binding sites on the membranes were blocked by incubation at +4°C for 6 h in PBS containing 3% BSA or 5% nonfat dried milk proteins (38) . The membranes were then incubated for 12 h with primary antibodies in PBS containing 0.05% Tween 20 and 1% BSA or 1% nonfat dried milk proteins (38) . The membranes were washed three times (30 min each) with the same buffer without antibodies and incubated for 4 h in the presence of '25I-labeled secondary antibodies. The membranes were then washed six times over 12 h in the same buffer without antibodies, dried, and subjected to autoradiography.
Antibodies. Six previously characterized MAbs specific for apo-B were used: MB-47 and MB-43, specific for apo B thrombin fragment T2; MB-44, specific for T3; MB-24, MB-19, and MB-3, specific for fragment T, (38) (39) (40) . In addition, polyclonal antisera against human LDL (39), MDA-LDL (18) , and reduced 4-HNE-LDL (18) were used. The antiserum against MDA-LDL (MAL-2) is specific for MDA-lysine adducts and recognizes this epitope on a variety of different proteins (18) . Similarly, the antiserum against 4-HNE-LDL (4-HNE) is specific for the 4-HNE-lysine adduct (18) . A full characterization ofthese antisera will be reported elsewhere.2 A MAb specific for human albumin (41) was also used. 251I-labeled affinity-purified goat IgG specific for human IgG, mouse IgG, rabbit IgG, or guinea pig IgG were used as secondary antibodies on Western blots. Antibodies were labeled using the lactoperoxidase method (Enzymobeads) according to the manufacturer's instructions. Typically, 1,000,000 cpm/10 41 of the antibody solution was used per 10 ml of the Western blot incubation buffer.
Lipoprotein modification and radioiodination. Copper-oxidized LDL was made by incubating LDL (100 ,ug/ml) at +37°C in Ham's F-10 for 3 h or 18 h in the presence of 10 ,uM cupric sulfate (42) . MDA-LDL was prepared at +4°C by repeated additions of freshly prepared MDA. MDA was liberated by incubating 0.1 ml tetramethoxypropane with 0.5 ml 4 N HCI at +60°C for 30 min. The solution was neutralized with 4 N NaOH and brought to 2.7 ml with distilled water. 10 ul of this solution was added to LDL (2 mg in 0.8 ml PBS containing no EDTA) in 5-min intervals during 3 h. After the additions, LDL was extensively dialyzed against PBS. Acetylated LDL (43) and reduced 4-HNE-LDL2 (27) were made as described. The extent of LDL modification was checked by agarose electrophoresis.
Lipoproteins were labeled with carrier-free sodium '251I-iodide using the Iodogen method (44). To ensure equal conditions of iodination, lesion LDL and control plasma LDL were always iodinated simultaneously at the same protein concentration. Specific activities varied from 50 to 450 cpm/ng lipoprotein protein. The percentage of 1251 radioactivity precipitated by TCA was > 96%.
Cell culture studies. Resident mouse peritoneal macrophages (MPM) were isolated from Swiss Webster mice as described (14) . Before the experiments, the cells were incubated for 24 h in DME containing 3.3 mg/ml LPDS. Human monocyte-macrophages were isolated (45) and cultured in Iscove's medium supplemented with 30% human serum, 8 ug/ml insulin, and 2 mg/ml glucose for 6-8 d. Before the incubations, the cells were incubated for 24 h in Iscove's medium containing 5 mg/ml LPDS.
Macrophage degradation of '25I-labeled lipoproteins was carried out by incubating the cells for 6 h in DME medium containing 3.3 mg/ml of LPDS and 2 or 5 yg/ml of the labeled lipoproteins, followed by the determination of the noniodide TCA-soluble radioactivity (46) .
The incorporation of ['4C]oleate into cellular cholesteryl esters was
studied by incubating the cells in the presence of 0.2 mM ['4C]oleate/ albumin, 3.3 or 5 mg/ml LPDS, and 25 Mg/ml ofthe lipoproteins (47) .
Cellular lipids were extracted in situ using hexane-isopropanol (3:2; vol/vol). Labeled cholesteryl esters were isolated using TLC and 2. Palinski, W., S. Yla-Herttuala, M. E. Rosenfeld, S. W. Butler, S. A. Socher, S. Parthasarathy, L. K. Curtiss, and J. L. Witztum, manuscript in preparation.
counted for ['4C1 radioactivity. All lipoproteins were sterile filtered (0.45 um) immediately before the cell culture experiments.
Chemotaxis assay. Chemotaxis was measured in a modified Boyden chamber using freshly prepared human monocytes as described (48) .
Results
Extraction of aortic LDL. In this study, fresh human and WHHL rabbit arteries were subjected to the gentlest possible extraction in the presence of antioxidants, antibiotics, and protease inhibitors. We believe this is critically important if one is to understand the nature ofthe lipoproteins as they exist in the intima. Homogenization or other vigorous extraction procedures can readily lead to denaturation, aggregation, and even to the generation of artifactual lipid-protein complexes. The latter may have some of the properties of lipoproteins but they may be actually created during the process of isolation. In all of the studies reported here, a sample of plasma LDL was taken from the organ donor or from the animal donor and subjected to exactly the same procedures used in the handling of the tissue LDL. We found no evidence for oxidation of the control plasma LDL studied in this way. Furthermore, when plasma LDL (0.25 mg) was added to minced normal or atherosclerotic intimal tissue (1 g) and then reisolated by the standard procedure, there was no evidence of oxidative modification as shown by SDS-PAGE, Western blotting with MB-47 and MAL-2, and by cell culture studies (data not shown).
To estimate the recoveries of LDL from the artery, trace amounts of 1251I-labeled WHHL rabbit plasma LDL (107 cpm total radioactivity per animal) were injected into five WHHL rabbits 2 h before killing. At killing, 1 g of lesion contained -0.0003% of the total injected radioactivity. Of the 251I-LDL in the artery wall at that time, 50-60% could be recovered using our standard extraction procedure. When the extraction was repeated using a buffer of higher ionic strength (1.5 M NaCl), only an additional 10-15% of the total '251-LDL was extracted. Whether or not the residual lipoprotein that cannot be removed by gentle extraction represents modified or unmodified LDL cannot be determined. Similarly, it is unclear what percent of LDL chronically present in the artery wall is extracted by our procedure. Nevertheless, because of the risk ofproducing artifacts, we did not use more vigorous extraction procedures but studied only that LDL that was readily removed into the buffer using the standard gentle procedure. In addition, to avoid using any lesion LDL that may have been aggregated, all samples were sterile filtered before the studies described below.
Physical and chemicalproperties oflesion LDL. On density gradient ultracentrifugation, lesion LDL appeared to be a single peak. The distribution of total cholesterol and of immunologically detectable apo B across the density gradient were nearly identical (Fig. 1 A) . The density of lesion LDL was higher than that of the corresponding control plasma LDL (Fig. 1 B, Table I ), but the density of the LDL isolated from normal human intima was not increased (Table I) . The relative electrophoretic mobility of human and WHHL rabbit lesion LDL was increased (Table I) . LDL isolated from normal human intima also had an increased electrophoretic mobility relative to plasma LDL (Table I ).
The total cholesterol to protein ratio of both human and WHHL rabbit lesion LDL was increased compared with that Figure 1 . Density profile of LDL isolated from plasma and from atherosclerotic lesions of WHHL rabbits. The density of the samples was brought to 1.18 g/ml by the addition of solid NaBr. A 6.50-ml sample of the d = 1.18 g/ml solution containing the lipoproteins was overlayered with 5.40 ml of d = 1.004 g/ml solution and centrifuged at 150,000 g for 40 h at +5°C as described in Methods. Fractions were collected from the top of the tubes and their densities measured with a Mettler-Paar densitometer. (A) Distributions of total cholesterol and immunoreactive apo B across the gradient containing the crude extract of WHHL rabbit lesion LDL. (B) Density distribution of '25W-labeled WHHL rabbit plasma LDL and lesion LDL. Both lipoproteins were isolated as described in Methods, radioiodinated and aliquots of the labeled lipoproteins were mixed with unlabeled carrier lipoproteins. All samples were pooled from eight animals. in their respective plasma LDL. Of the total cholesterol in WHHL rabbit lesion LDL, 66% was in free form, whereas in WHHL rabbit plasma LDL only 24% of the total cholesterol was free (Table I) . Because of the relatively small amount of LDL extractable from even atherosclerotic arterial tissue, composition analysis was done only on one preparation of WHHL rabbit lesion LDL (combined from eight animals). The percentage composition of lesion LDL was as follows: free cholesterol, 29.0%; cholesteryl esters, 27.5%; phospholipids, 21.8%; triglycerides, 6.4%; and total protein, 15.3%. Corresponding values for WHHL rabbit plasma LDL were: 11.5, 42.9, 22.9, 5.6, and 17.1%, respectively. Phospholipid subfractions in the same lesion LDL were (percentage of total phospholipids): lysophosphatidylcholine, 10.4%; phosphatidylcholine, 25 No increased amounts of TBARS could be found in lesion LDL. This observation is not unexpected because of the known loss of the polar TBARS that occurs during the ultracentrifugation and dialysis involved in purification of lesion LDL (28, 29) .
Immunologic studies oflesion LDL. In all lesion LDL samples studied, Western blot analyses with the apo B-specific MAb MB-47 showed an extensive degradation of lesion LDL apo B (Fig. 2) . Less apparent breakdown of apo B was evident with five other apo B-specific MAbs (Fig. 3) , presumably because these antibodies did not detect some of the fragments that MB-47 did. Some breakdown products were even found in control plasma LDL, which is probably due to the high sensitivity of the Western blotting method. It is noteworthy q <9 2  43  44 bands. In general, no such reactions were found with the patient's plasma LDL or with LDL isolated from normal human aortic intima (Fig. 4 ). In occasional plasma LDL samples, F w_ _ _~~~~~~therewas weak staining of apo B-1I00 by the antiserum to 4-HNE ( Fig. 4 ) as well as by MAL-2. In the plasma LDL we never observed apo B fragments that were stained with MAL-2 or 4-HNE antisera. Small amounts of albumin and immunoglobulins (see below) were also detected in the isolated lesion LDL, but no albumin was present in the major MDA-positive bands (Fig. 4) . Some of the MAL-2 positive bands in lesion LDL also coincided with the bands recognized by the apo B specific MAbs, MB-19 ( Fig. 5 ), MB-3 and MB-43 (data not -; 1 _9 : 1 < shown). a human lesion LDL (male, age 41 Essentially similar results were obtained with lesion LDL ferent apo B-specific antibodies. Apo-isolated from WHHL rabbit atherosclerotic aortas. As shown 4-12% SDS-PAGE under nonreduc-in Fig. 6 (Figs. 3 and 4) , as viously shown that oxidized LDL, but not native LDL, is chehen LDL was isolated from both motactic for human monocytes (48) . LDL isolated from both from atherosclerotic lesions of the human and WHHL rabbit lesions was also chemotactic for ilotted with MB-47, normal intimal human monocytes, whereas plasma LDL and LDL isolated degradation products than lesion from normal human intima were not (Table II) .
Human lesion LDL stimulated the incorporation of [14C]-Dcular weight fragments in lesion
oleate into cellular cholesteryl esters ofhuman monocyte-mac-)dies raised against MDA-LDL rophages sixfold relative to an LPDS control (Table III) ; the NE-LDL (4-HNE) (Fig. 4) . These stimulation by human plasma LDL was only twofold. LDL sine adducts and 4-HNE-lysine ad-isolated from the lesions of WHHL rabbits increased cholesids staining with MAL-2 coincided terol esterification in MPM fourfold (Table IV) whereas th the apo B-specific MAb MB-47.
WHHL plasma LDL had almost no effect. Compared with The degradation of '25l-labeled WHHL rabbit lesion LDL in MPM was increased eightfold compared with that of WHHL plasma LDL (Table V) . As shown in Fig. 7 , the degradation of WHHL rabbit lesion '25I-LDL was competed by unlabeled lesion LDL, poly I, MDA-LDL, and LDL oxidized with copper for 18 h. Acetyl-LDL and LDL oxidized with copper for only 3 h were less effective, whereas WHHL rabbit plasma LDL did not compete. Previous studies have shown that oxidized LDL is recognized and degraded poorly by the native LDL receptor of fibroblasts (12, 29) . At the concentration of 20 ,ug lipoprotein protein/ml incubation media, WHHL rabbit '251I-labeled lesion LDL was only marginally degraded by human fibroblasts (0.1 gg/mg cell protein/6 h), whereas WHHL rabbit plasma LDL was readily degraded (4.1 Ag/mg cell protein/6 h). 
Silver MB-47 Discussion
These studies present three lines ofevidence for the presence of oxidatively modified LDL in human and in rabbit atherosclerotic lesions. First, lesion LDL greatly resembles oxidized LDL in its physical and chemical properties. Lesion LDL as isolated showed a reasonably sharp density profile (Fig. 1 ) with a modal density slightly greater than that of plasma LDL, as is the case for oxidized LDL (l1). In agreement with previous findings, lesion LDL had increased electrophoretic mobility (19, (21) (22) (23) (24) (25) (26) , contained more free cholesterol (23, 25, 26) and had a higher percentage oflysophosphatidylcholine in the total phospholipids ( tion, there was extensive fragmentation of apo B, typical of oxidatively modified LDL (42) . A second line of evidence comes from the use of immunologic techniques. The antisera used here were specific for epitopes present in oxidized LDL but absent from native LDL. They were generated using models of oxidized LDL, i.e., MDA-conjugated LDL and 4-HNE-conjugated LDL. These are among the several modifications of apo B generated by aldehyde fragments, formed during oxidation of polyunsaturated fatty acids, which complex with epsiolon-amino groups of lysine residues (2, (27) (28) (29) . The model modified forms of LDL were injected into homologous species so that antibodies against the native LDL were not generated. Thus the antisera produced were adduct specific, i.e., MAL-2 recognizes MDAlysine residues (present on any protein) and antiserum 4-HNE recognizes 4-HNE-lysine residues (present on any protein). As expected, Western blot analysis with these antisera showed no reaction with native, plasma LDL. In contrast, Western blot analysis showed that in lesion LDL, but not in LDL isolated from normal human intima, both the intact apo B-100 band and several of the apo B fragments generated during oxidative modification reacted strongly with these antisera (Fig. 4) .
Although the analyses were done on a fraction of lipoprotein isolated at or near plasma LDL density, and even though the material was refloated three times, it might be argued that other intimal proteins remained adherent to the LDL. We have preliminary data indicating that traces of immunologically detectable immunoglobulins (Fig. 6 ), proteoglycans and fibronectin remain associated with LDL isolated from lesions (Yla-Herttuala, S., J. L. Witztum, and D. Steinberg, unpublished observations). The possibility that these, rather than the apo B of LDL, might contain the epitopes reactive with the antisera is made much less likely, however, by the fact that the fragments react both with antibodies specific for apo B and with antibodies specific for the MDA and 4-HNE epitopes (Figs. 4-6). A third and most compelling line ofevidence is the demonstration that lesion LDL shares many biological properties of oxidized LDL. Like oxidized LDL, intimal LDL showed chemotactic activity for human monocytes, whereas LDL isolated from normal human intima was not chemotactic. We previously reported that oxidatively modified LDL is chemotactic for monocytes (and not for neutrophils) (48) partly by virtue of its content of lysophosphatidylcholine (49) . However, in view of the large number of chemotactic factors that might be present and that might bind to the LDL, we cannot rule out some other factor as being responsible for the observed activity.
Additional biological evidence that lesion LDL resembles oxidatively modified LDL comes from the competition studies ofthe degradation of lesion LDL in MPM. We showed that the degradation of '251-labeled WHHL rabbit lesion LDL was competed for by unlabeled lesion LDL, MDA-LDL, LDL oxidized with copper for 18 h, and poly I. Acetyl LDL and LDL oxidized with copper for only 3 h were less effective, whereas plasma LDL did not compete for the degradation of lesion LDL. Only a few studies have previously tested the ability of various modified LDL preparations to compete for the degradation of '25I-labeled lesion LDL. Morton et al. (23) found that the degradation of lesion LDL isolated from postmortem aorta was not competed for by acetyl LDL or unlabeled lesion LDL, whereas Shaikh et al. (25) reported that the degradation of lesion LDL was competed effectively by acetyl LDL. The reason for the contradictory results between these studies remains to be identified, but it may arise from differences in the tissue samples, isolation procedures and/or the cell lines used. Consistent with earlier reports, arterial LDL in the present studies stimulated oleate incorporation into MPM (20, 22-26) and human monocyte-macrophages (25) by several fold compared with normal plasma LDL.
It is noteworthy that in our competition assays, acetyl LDL was a much less effective ligand than LDL oxidized with copper for 18 h. Recent studies by Sparrow et al. (50) and Arai et al. (51) suggest that macrophages express a second class of receptors that bind oxidized LDL in addition to the acetyl LDL receptor. Degradation of oxidized LDL was only incompletely competed for by acetyl LDL (50, 51) . In the present study, lesion LDL degradation could not be completely competed (i.e., > 90%) by any of the tested ligands, suggesting that more than one process was responsible for the uptake and degradation. The presence of small amounts of IgG in the lesion LDL might suggest that macrophage F, receptor-mediated mechanisms may also be involved in the metabolism of lesion LDL. We have recently shown that autoantibodies for MDA-LDL exist in human and rabbit plasma (18) .
These studies do not permit us to specify either the proportion of the particles in total lesion LDL or the extent of lysine residues per lesion LDL particle that have been modified. It seems unlikely, however, that all of the particles in lesion LDL are modified in a similar way or to the same extent, since some of the particles may have just entered intima, whereas others may have been retained in the lesion for a prolonged time. Also, the modified lipoproteins presumably would be taken up rapidly by macrophages and thus leave a smaller proportion of heavily modified particles in the steadystate arterial wall pool of LDL. Nevertheless, these results show that, compared with the corresponding plasma LDL, LDL isolated from human and WHHL rabbit atherosclerotic lesions contains particles that have many physical, immunologic, and biologic properties resembling those characteristic of LDL oxidized in vitro (10-12, 14, 42, 52) . These data strongly support the conclusion that at least a portion ofthe LDL found in atherosclerotic lesions has undergone oxidative modification. That conclusion is further supported by the previously reported occurrence, both in rabbits and in man, of autoantibodies that bind to MDA-LDL and 4-HNE-LDL (18) . Finally, that antioxidant therapy inhibits lesion formation in the WHHL rabbit (15, 16 ) strongly attests to the importance of oxidized LDL to the atherogenic process. 
